Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (11-20 of 208) with videos related to

Pageof 21
Sort By:
Translational Andrology and Urology|May 26, 2017
Trimodality therapy in variant urothelial carcinoma: choose wiselyPanagiotis J Vlachostergios, Christopher Jakubowski, Scott T Tagawa
Advances in Urology|July 31, 2010
Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosisHimisha Beltran, Brian D Robinson, Scott T Tagawa
European Urology Focus|March 2, 2021
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and BeyondJones T Nauseef, Neil H Bander, Scott T Tagawa
JAMA Oncology|September 16, 2021
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to ProstatectomyJoseph R Osborne, Neil H Bander, Scott T Tagawa
Prostate Cancer|May 24, 2012
The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancerMichael J Smith, Naveed H Akhtar, Scott T Tagawa
The Journal of Urology|June 19, 2012
Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?Matthew D Galsky, Scott T Tagawa, Shahrokh F Shariat
Urologic Oncology|February 25, 2026
Cell-surface targets for prostate cancer therapeuticsSamuel Ruder, Pardis Ziaeefar, Ambika P Jaswal, et al.
Translational Andrology and Urology|February 9, 2026
Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 studyTobechukwu J Okobi, Neil Vaishampayan, Deepthi Subramanya, et al.
Cancer Treatment Reviews|May 21, 2017
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancerGiuseppe Galletti, Benjamin I Leach, Linda Lam, et al.
Current Treatment Options in Oncology|March 13, 2015
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancerElan Diamond, María del Carmen Garcias, Beerinder Karir, et al.
Pageof 21

Showing results (11-20 of 208) with videos related to

Sort By:
Pageof 21
Translational Andrology and Urology|May 26, 2017
Trimodality therapy in variant urothelial carcinoma: choose wiselyPanagiotis J Vlachostergios, Christopher Jakubowski, Scott T Tagawa
Advances in Urology|July 31, 2010
Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosisHimisha Beltran, Brian D Robinson, Scott T Tagawa
European Urology Focus|March 2, 2021
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and BeyondJones T Nauseef, Neil H Bander, Scott T Tagawa
JAMA Oncology|September 16, 2021
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to ProstatectomyJoseph R Osborne, Neil H Bander, Scott T Tagawa
Prostate Cancer|May 24, 2012
The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancerMichael J Smith, Naveed H Akhtar, Scott T Tagawa
The Journal of Urology|June 19, 2012
Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?Matthew D Galsky, Scott T Tagawa, Shahrokh F Shariat
Urologic Oncology|February 25, 2026
Cell-surface targets for prostate cancer therapeuticsSamuel Ruder, Pardis Ziaeefar, Ambika P Jaswal, et al.
Translational Andrology and Urology|February 9, 2026
Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 studyTobechukwu J Okobi, Neil Vaishampayan, Deepthi Subramanya, et al.
Cancer Treatment Reviews|May 21, 2017
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancerGiuseppe Galletti, Benjamin I Leach, Linda Lam, et al.
Current Treatment Options in Oncology|March 13, 2015
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancerElan Diamond, María del Carmen Garcias, Beerinder Karir, et al.
Pageof 21